Cole Jennifer, Busti Anthony, Kazi Salahuddin
Department of Pharmacy, Veterans Affairs North Texas Health Care System (VANTHCS), Dallas, TX, USA.
Rheumatol Int. 2007 Feb;27(4):369-73. doi: 10.1007/s00296-006-0215-3. Epub 2006 Oct 7.
The objective of this study was to evaluate the incidence of new onset or worsening congestive heart failure in Veteran's Affairs (VA) patients who have received infliximab, etanercept, or adalimumab, and to compare mortality rates in these patients to control populations. We enrolled three groups of patients for this retrospective study: TNF-alpha group (n = 103), a rheumatoid arthritis (RA) control group (n = 100), and a control group without RA (n = 100). All patients at our VA facility who had received at least one dose of the TNF-alpha antagonists were included in the TNF-alpha group. Admissions for CHF did not differ between the three groups: TNF-alpha 7 (6.7%), RA control 8 (8%), non-RA control 7 (7%); P = 0.940. Mortality rates were not significantly different: TNF-alpha 4 (3.8%), RA control 7 (7%), non-RA control 11 (11%); P = 0.147. Our study showed no difference between the three groups in either CHF exacerbation or mortality.
本研究的目的是评估接受英夫利昔单抗、依那西普或阿达木单抗治疗的退伍军人事务部（VA）患者中新发或加重的充血性心力衰竭的发生率，并将这些患者的死亡率与对照组进行比较。我们为这项回顾性研究招募了三组患者：肿瘤坏死因子-α（TNF-α）组（n = 103）、类风湿性关节炎（RA）对照组（n = 100）和无RA的对照组（n = 100）。我们VA机构中所有接受过至少一剂TNF-α拮抗剂治疗的患者都被纳入TNF-α组。三组间因充血性心力衰竭入院的情况无差异：TNF-α组7例（6.7%），RA对照组8例（8%），非RA对照组7例（7%）；P = 0.940。死亡率无显著差异：TNF-α组4例（3.8%），RA对照组7例（7%），非RA对照组11例（11%）；P = 0.147。我们的研究表明，三组在充血性心力衰竭加重或死亡率方面均无差异。
